跳到正文
openFDA 已分级药品召回执法报告·· 26 天前精选AI 评分64

FDA 执法报告 D-0049-2027 将 Viatris 替米沙坦氨氯地平片超效价召回列为 III 类

FDA drug enforcement D-0049-2027: Viatris, Inc. — Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications

AI 导读

openFDA 执法报告 D-0049-2027 记录 Viatris 公司自愿召回替米沙坦氨氯地平片 40mg/5mg(30 片/瓶),原因是相关批次替米沙坦含量可能超出标准,属于超效价风险,被列为 III 类。

推荐理由

记录给出了超效价风险涉及的具体批号、有效期与分销范围,可用于核对召回边界与批次覆盖。

正文 · AI 翻译

FDA 药品召回执法报告 — D-0049-2027

报告发布日期:2026-10-28。这是执法报告日期,不是召回启动日期。

范围:一条已分类的药品召回记录;event_id 可能归组多个产品。无召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。

openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所表示的含义。

完整官方产品记录(含 openFDA 统一标识符):

{

"address_1": "3711 Collins Ferry Rd",

"address_2": "",

"center_classification_date": "20261016",

"city": "Morgantown",

"classification": "Class III",

"code_info": "批号 3228113、3228114、3228115,有效期:2026年10月31日;批号 3228120、3228121,有效期:2026年11月30日。",

"country": "United States",

"distribution_pattern": "美国全国范围。",

"event_id": "100048",

"initial_firm_notification": "信函",

"more_code_info": "",

"openfda": {

"application_number": [

"ANDA202516"

],

"brand_name": [

"TELMISARTAN AND AMLODIPINE"

],

"generic_name": [

"TELMISARTAN AND AMLODIPINE"

],

"is_original_packager": [

true

],

"manufacturer_name": [

"Mylan Pharmaceuticals Inc."

],

"nui": [

"N0000000070",

"N0000175561"

],

"package_ndc": [

"0378-1075-93",

"0378-1076-93",

"0378-1077-93",

"0378-1078-93"

],

"pharm_class_epc": [

"血管紧张素2受体阻滞剂 [EPC]"

],

"pharm_class_moa": [

"血管紧张素2受体拮抗剂 [MoA]"

],

"product_ndc": [

"0378-1075",

"0378-1076",

"0378-1077",

"0378-1078"

],

"product_type": [

"人用处方药"

],

"route": [

"口服"

],

"rxcui": [

"876514",

"876519",

"876524",

"876529"

],

"spl_id": [

"c4f4323d-671d-478b-b088-008530932cee"

],

"spl_set_id": [

"ca60a4d5-ace7-4889-94ee-e2265fd63811"

],

"substance_name": [

"TELMISARTAN",

"AMLODIPINE BESYLATE"

],

"unii": [

"U5SYW473RQ",

"864V2Q084H"

],

"upc": [

"0303781075930",

"0303781076937",

"0303781078931",

"0303781077934"

]

},

"postal_code": "26505-2362",

"product_description": "替米沙坦和氨氯地平片,USP,40mg/5 mg,30片装瓶,处方药,受托生产方:Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA,印度制造,NDC 0378-1075-93。",

"product_quantity": "21,620 瓶(30片装)",

"product_type": "药品",

"reason_for_recall": "药物含量超标:这些批次中替米沙坦含量可能超出标准",

"recall_initiation_date": "20261001",

"recall_number": "D-0049-2027",

"recalling_firm": "Viatris, Inc.",

"report_date": "20261028",

"state": "WV",

"status": "进行中",

"voluntary_mandated": "自愿:企业发起"

}

来源:openFDA 已分级药品召回执法报告 · api.fda.gov